We checked all medical records to see whether the recommendation were applied or not between the last consultation before (Tour 1; T1) and after (Tour 2; T2) the introduction of the national guidelines. Results. -Twenty-seven medicals records with classic CAH were analyzed. The collection of clinical data must be more systematic because if the weight appeared in 89% of cases, body mass index missed (26% only in T1), the measure of the blood pressure remained insufficient (74% in T2). Concerning the therapeutic balance, 17-hydroxyprogestérone, testosterone, renin were correctly prescribed (> 80%), Delta4-androstènedione in improvement (from 67% to 100%) some in defect (stable with 68% sodium and potassium). The evaluation of the fertility considerably progressed on the other hand the markers of bone metabolism were still often too much lacking. Le recueil des données cliniques doit être plus systématique, car si le poids figurait dans 89 % des dossiers, le calcul de l'indice de masse corporelle manquait (26 % seulement au T1), la mesure de la tension artérielle restait insuffisante (74 % au T2). Concernant l'équilibre thérapeutique, la 17-hydroxyprogestérone, la testostérone, la rénine étaient correctement prescrits (> 80 %), d'autres en amélioration (de 67 % à 100 % Delta4-androstènedione) certains à défaut (stable à 68 % natrémie et kaliémie). L'évaluation de la fertilité a considérablement progressée, en revanche, les marqueurs du remodelage osseux font encore trop souvent défaut. Conclusion. -L'amélioration des pratiques professionnelles après la parution d'un référentiel national n'est ni immédiate ni complète.
Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder affecting adrenal steroid synthesis. The most From [3] .
common form of CAH (in about 95% of the cases) is due to mutations in CYP21, the gene encoding the adrenal steroid 21-hydroxylase enzyme (P450c21) in the zona fasciculata and zona glomerulosa of the adrenal cortex. This enzyme converts 17-hydroxyprogesterone (17-OHP) to 11-desoxycortisol and progesterone to deoxycorticosterone, respectively precursors for cortisol and aldosterone. It results a lack of cortisol and, if severe, in aldosterone [1, 2] . The cortisol deficiency results in stimulation of adrenocorticotropic hormone (ACTH) release and an accumulation of cortisol precursors that are diverted to sex hormone biosynthesis (Figs. 1 and 2). The syndrome is characterized by a considerable correlation between the genotype and the phenotype with the type of CYP21 gene mutation affecting the severity of 21-hydroxylase deficiency (21-OHP). More than 100 CYP21 mutations are known within chromosome 6p21. 3 . Y MOREL illustrated the correlation between clinical forms and the main mutations in CYP21 thanks to Fig. 3 [3] . Three main types of CAH are distinguished depending on the residual enzymatic activity:
• classic salt-wasting CAH (SW CAH); complete lack of 21- hydroxylase activity in the adrenal cortex leading to cortisol and aldosterone deficiency; • classic simple virilising CAH (SV CAH); only 1-2% of 21-hydroxylase activity is preserved. Cortisol deficiency is present but no clinical manifestations of aldosterone deficiency are observed; • non-classic CAH (NC CAH); 20-50% of 21-hydroxylase activity being preserved which results in a mild subclinical in late childhood or during puberty [4] [5] [6] [7] [8] .
The mean prevalence of classic CAH has been established at about 1 in 15,000 live birth [9] . The prevalence is much higher in some ethnic groups (1 in 280 among the Yupik Eskimos inhabiting Alaska and 1 in 2100 among the inhabitants of the French island Reunion). For classical CAH, the carrier frequency in France is approximately one in 50 individuals (in both sexes). Since 1995 in France, 21-hydroxylase deficiency is incorporated into all screening programs. In fact, CAH is common and potentially fatal. Early recognition and treatment can prevent morbidity and mortality. The death rate in salt-wasting CAH without screening is between 4 to 10% [10] .
Since the introduction of cortisone therapy by Wilkins et al. in the early 1950s [11] , the children have been able to survive into adulthood. The principal goal of treatment in adults with CAH is to improve quality of life, ensure that they remain fertile, reduce the manifestations of hyperandrogenization in females, and minimize the adverse effects of glucocorticoid treatment like metabolic syndrome, cardiovascular disease and osteoporosis [12] [13] [14] [15] . Despite over 50 years of experience, the management of CAH remains difficult, and clinical practice varies substantially in the world. To consider the evidence for best practice, to formulate management guidelines, and to consider innovative therapies, the French High Authority for Health (HAS) edited in April 2011 a national program of care and diagnostic; (PNDS) [16] in agreement with the international recommendation 2002 [17] and 2010 [18] .
CAH belongs to a group of rare endocrine disease of growth, disease of sexual development and adrenal rare disease. In fact, very few patients in our endocrine unit are affected by 21-hydroxylase deficiency. It seemed to be necessary to homogenize the care of our patients. That is why we conducted a clinical audit to compare, which is at present made and what should be made according to the national guidelines. Then, we are trying to explain why it is necessary to our opinion to follow the practice guidelines or not and will try to propose our own management guidelines. The objective was to improve our professional practice in order to improve quality of life to our patients.
Method and patients

First step
We aimed to identify all patients aged more than 18 years with classic CAH, identified through search in electronic diagnostic registries at the adult endocrine units in the Nancy's University Hospital Center. In our unit, four physicians are in charge of patients with CAH. Twice of them are gynecologists and endocrinologists. Actually, those patients are systematically referred to the same medical doctor. It is a common practice for years. We started by listing patients thank to the International Classification of Disease codes 255 and E25; adrenal syndromes and unspecific adrenal diseases in the endocrine pediatric unit. Then we found by key word in our informatics system of correspondence to list further patients. About fifty medical records were studied in a few days. The CAH diagnosis was verified by scrutiny of original medical records in all the patients, including data on genital examination, symptoms at presentation, level of adrenal steroids, and genetic analyses. We have only kept 27 patients. The older patient was born in 1961 and the younger in 1994. As a consequence, we are confronting with a very heterogeneous cohort. Indeed three doctor's generations were brought to take care of these patients. They were completely different in the demographic, anthropologic, social and economic aspects.
Second step
Thanks to the monitoring protocol according to the age proposed by the PNDS (Table 1) , we checked all medical records to see whether the recommendation were applied or not from April 2011. We have made a clinical audit between the Tour 1; i.e. "T1" the last consultation before the introduction of the national guidelines [16] and the Tour 2; i.e. "T2" after the publication.
Third step
To each criterion, three responses were possible: No it was not realized; Yes it was realized; NA not applicable. Thanks to an Excel program we were able to compare the percentage of No, Yes and NA between time 1 and time 2. We presented the results thanks to graphic to make it more understandable.
Results
We analyzed 27 medical records with classical CAH at the adult endocrine unit in Nancy's University Hospital Center. All but two were followed before in the endocrine pediatric unit. Diagnosis was confirmed by genetic analyses in 74% of patients. Data concerning genetic analyses for seven older patients were not found. Among 27 patients, 22 were SW and nine were SV. There were 19 females and eight males patients; age range 18-50 years. All but three received exclusively hydrocortisone given three times daily, the other were treated with dexamethasone (0.5 mg/day given on the evening). The 22 SW received 9-alphafludrocortisone given twice daily.
About clinical elements, weight, height, body mass index (BMI) and blood pressure (TA) were analyzed. Between T1 and T2 the weight is often find in the medical record with no difference in 89% of the medical records. Height and BMI were found only in 41% and 26% respectively in T1 but it is better in T2 with 89%. The 11% represent the three patients who have not been seen since April 2011. To the blood pressure, it is acceptable with 63% and 74% respectively T1 and T2 (Table 2 and Fig. 4) .
The principal biochemical parameters used to monitor glucocorticoid treatment include 17-OHP, Delta4-androstenedione and testosterone. 17-OHP is presented in 81% and 100% between T1 and T2, Delat4-androstenedione and testosterone are found in 41% and 67% but at T2 in 92 and 100% respectively.
Renin is the basic biochemical parameter used in the monitoring of fludrocortisone treatment [13, 19] . It is found in Table 2 Results of audit clinic: clinical and paraclinical parameters studied before and after the national recommendation in April 2011. respectively 67 and 88% in T1 and T2. Sodium and potassium are two other biochemical parameters that reflect water and electrolyte balance in patients on mineralocorticosteroids.
There is no real difference between the results before the national guidelines and those after since the percentages are 63% and 68% to sodium and 63% and 60% to potassium (Table 2 and Fig. 5 ).
Concerning the fertility, follicle-stimuling hormone (FSH) and luteinizing hormone (LH) were found in 22% at T1 and 96% at T2. To estrogen, it was 26% and 88% and to progesterone 0% before and 46% after. Concerning exclusively the men fertility inhibin B was never found in T1 (0%) but found in 88% of cases after the recommendations (Table 2 and Fig. 6 ). We had not check anti-müllerian hormone (AMH) because to the PNDS, it was only necessary at the beginning of puberty.
About the markers of bone metabolism, calcium, phosphor, alkaline phosphatase were studied in 58% in T2 versus 33%, 22% and 11% respectively in T1. In T2, we analyzed PTH and vitamin D in 67% versus 15% and 7% in T1 (Table 2 and Fig. 7) .
The metabolic syndrome was appreciated thanks to glycaemia and insulin. Unlike, glycaemia was well prescribed in T1 (81%) and in T2 (100%), insulin serum was only studied in T2 in 46% of cases (Table 2 and Fig. 8 ).
The bone mineral density (BMD) is recommended to be checked at the end of puberty. Only 33% used to be studied but after the recommendation it was considered in 78% of the cases (Table 2 and Fig. 9 ).
Finally, ultrasonography may demonstrated gonad morphology and contributes to impaired fertility. At the beginning of puberty, pediatric endocrinologist was not used to check it (30%) but in transition it was well studied in 89% of cases (Table 2, Figs. 10 and 11).
After this work, we expect to improve the follow-up in our patients with CAH. Thus, we are trying to propose clinical and paraclinical recommendations useful in routine (Appendix A and Appendix B).
Discussion
Despite over 50 years of experience with steroid replacement therapy, the management of CAH remains difficult, and clinical practice varies substantially throughout the world. The French Society of Endocrinology (SFE) agreed with the following consensus statement [16] . Consensus was guided by systematic reviews of evidence and discussions [17, 18] . To improve our medical practice it is necessary to be in accordance with the recent guidelines. As a consequence we realized a clinical audit to confront our patterns with the national recommendation.
In our study we are much better in the clinical aspect like (weight, height, BMI and blood pressure). In fact, in approximately 100% of case these elements were found in the medical records. It is also much better to the biochemical parameters necessary to monitor glucocorticoid and mineralocorticoid treatment. The main markers were present in more of 80% of cases. However, ACTH was usually checked (67%) unlike it was not recommended by any national or international endocrine Society. Concerning the fertility, it is surprising that gonadotrophines were not analyzed since the main physician who follows this population is an endocrinologist and gynecologist. The main explanation is the fact that we are dealing with a young population without fertility project. However, since new guidelines it is much better and ultrasonography in women patients still well studied. Finally, we have to improve in the evaluation of markers of bone density as well as biologic markers and bone mineral density. Now, we are trying to explain why it is necessary to our opinion to follow the practice guidelines or not and will try to propose our own management guidelines.
Height
Treatment for patients with CAH may affect the final height of these patients. A systematic review and meta-analyses were conducted to determine the distribution of achieve height in patients with classic CAH [20, 21] . The final height SDS achieves by CAH patients was -1.38 lower than the population norm. The corrected height SDS was -1.03. In our cohort, mean final height was -1.5 SDS (155.7 cm) in women and -0.5 SDS (167 cm) in men while the target height was -0.9 SDS (161 cm) and +0.4 SDS (176.56 cm) respectively. As adult endocrinologists, we are not implicated in this part of the follow-up. In fact, height is influence by many factors, namely age at diagnosis [21] , dose of glucocorticoid therapy [22] , adequacy of treatment [23] and form of CAH [24] . However, witch seems to be important is the fact that there is no significant relationship between height and measures of friendship, popularity or reputation with peers [25] . So even if, the final height of CAH patients treated with glucocorticoids is lower than the population norm and is lower than expected given parental height it seems not impact in their quality of life.
Weight and body mass index
In the late 1980s, Knorr et al. [26] reported an increased rate of obese patients with CAH. Seventy-five percent of the over treated children developed obesity after their 6th year of life. Cornean et al. [27] found an adiposity rebound three years earlier than the general population. The median adiposity rebound was attained at 1.74 years compared with 5.5 years in the general UK population [27] . In recent years, there has been an enormous effort to identify factors contributing to the higher risk of obesity in children and adolescents with CAH. To Völkl et al. [28] hydrocortisone dosages, chronologic age, advanced bone maturation, and parental obesity contributed to elevated BMI SD, whereas birth weight and length, fludrocortisone dosage and serum leptin levels were not associated with obesity. The last point is controversial. Actually, Charmandari et al. [29] found a leptin level higher in children with CAH. Moreover, leptin concentration is negatively and significantly correlated with epinephrine and free metanephrines concentrations, this may reflect the adrenomedullary hypofunction in CAH. Dysfunction leptin's axis contributes to increase the risk of overweight and obesity in CAH. Unfortunately no study about leptin regulation was performed in the adult CAH. This part of discussion addresses to the pediatric endocrinologists, who have to be extremely vigilant to minimize the risk of obesity in children with CAH.
Concerning adult weigh, a large numbers of studies reporting on higher rates of overweight and obesity (Table 3) [30] [31] [32] [33] [34] [35] [36] [37] . A recent study [37] , show that both men and women with CAH had higher BMI than the control population. Overall, 41% of CAH patients had a BMI in the obese range (> 30 kg/m 2 ) and 37% were overweight (> 25-30 kg/m 2 < ). After adjusting for age, prevalence of obesity was 37.1% in men and 52.2% in women with classic CAH versus 23.3% and 26.5% respectively. In the present study, there were as many obese patients as overweight as normal weight in both genders. Encouragement of physical activities, healthy food, and more optimal glucocorticoid therapy remain very important. We have to weight, measure and calculate BMI in every consultation. Actually, it is clear that patients with CYP21 are at risk of obesity, which has important implications for the evolution of diabetes, hypertension, and cardiovascular disease in these subjects [38] .
Metabolic syndrome
Few studies have addressed the consequences of longterm glucocorticoid therapy on metabolic risk factors and morbidity in cardiovascular disease during adult life [39, 40] . However, studies have been small, consisting mainly of young adults.
Higher blood pressure levels have been described in children and adolescents with CAH [41] . Concerning adult, hypertension has not been reported [33, 42] . Our study was in accordance with this result. However, Sartorato et al. [42] demonstrated in adults with CAH an increasing intima-media-thickness (IMT); precursors of clinically detectable atherosclerosis, associated with higher cardiovascular risk. They suggested that the increased IMT is independent of any cardiovascular risk factor such as BMI, high blood pressure, or lipid profile disruption.
Few studies show an alteration in lipid metabolism in adult CAH. Total fasting cholesterol and low-density lipoprotein cholesterol (LDL) was higher and high-density lipoprotein cholesterol (HDL) was lower in patients [37, 43] . In the present study, there was no indication that patients had a harmful lipid profile than controls. In the protocol proposed by the PNDS, lipid metabolism's study is not required. To our opinion, we have to find abnormalities in lipid metabolism minimum once a year. Glucocorticoid excess can lead to insulin resistance and diabetes [29] . In a recent study [33] , insulin levels were similar in younger patients (< 30 years) and controls, whereas older patients (> 30 years) had a modest elevation, compared with controls but with no difference significantly. Elevated androgens may lead to insulin resistance. If suppressed androgens in our patients may have modified insulin sensitivity remains speculative. Fasting blood glucose was lower in the patients, most likely reflecting cortisol deficiency before the morning glucocorticoid medication. The high frequency of gestational diabetes among patients indicates high risk of future diabetes [44] . In our study, no diabetes mellitus were reported, fasting blood glucose was normal. Unlike, insulin resistance is clearly demonstrated in CAH, we found little data in the literature occurred on diabetes. It is probably because we are confronted to a young population so further investigation seems to be necessary.
Bone mineral density
The primary treatment for patients with CAH due to 21-hydroxylase deficiency is glucocorticoid replacement therapy, which at supra physiologic levels can result in diminished bone accrual and lead to osteopenia and osteoporosis. While studies in children have found no BMD decreases [30] , studies in adults have demonstrated significantly lower BMD in patients with CAH versus controls [13, 35, 45, 46] (Table 4) . The group at highest risk of low BMD is patients with classic saltwasting CAH (SW), who are managed with the highest doses of glucocorticoids or with longer-acting glucocorticoid like dexamethasone. Falhammar et al. [46] first studied patients over 30 years of age. Signs of osteopenia were found in 73% of women with CAH versus 21% in control patient. Moreover, the frequency of fractures was significantly elevated. This is probably due to over-treatment with glucocorticoids, indicate by low androgens [32, 47] . In the present study, two patients had osteoporosis and one had osteopenia. No fracture was report. All but three had vitamin D deficiency. Osteoporosis prophylaxis such as physical activities, calcium and vitamin D supplementation could be considered. It is recommended to analyze bone mineral density at the end of puberty. If it is normal, all 5 in 10 years until the menopause, if osteopenia all 5 years and if osteoporosis all 2 years. After menopause, to the women without hormonal substitution treatment, BMD is necessary in 2 or 5 years then all 5-10 years. If treatment is begun, BMD have to be studied at the end.
Male fertility
Reduced fertility has been observed in small cohorts men with 21-OHD [48, 49] . Elevated adrenal androgen secretion may suppress the hypothalamic-gonadal axis with resultant small testes and decreased spermatogenesis. Over the last decade, it has become increasingly clear that testicular adrenal rest tissue (TRAT) can severely compromise fertility [50] . The prevalence of TRAT in men CAH is as high as 50%. The clinical manifestations include increased testicular volume and the presence of multiple firms, tender nodules. TRAT are often found in patients with poor hormonal control and high ACTH levels, suggested that ACTH is a dominant factor in tumor growth and are often reversible after adjustment of glucocorticoid treatment [51] . Our results were in accordance with the previously studies. Actually, Table 4 Bone mineral density (BMD) analysis in patients with congenital adrenal hyperplasia (CAH). poor therapy control was present in three patients; all three had TRAT while only two patients had physical abnormalities. At a minimum, men with 21-OHD should have an annual testicular exam, and screening ultrasonography is recommend because of in 42% of the patients with TRAT detected by sonography physical examination was normal [52] .
In spite of the use of doses of glucocorticoids patients with 21-hydroxylase deficiency remain exposed to an excess of androgens. The long-term analysis of the adolescents and young adults in the international literature is only reported in small studies (n = 30 patients in most), dedicated to the analysis of restricted phenotypes: size, testicular inclusions, speed of growth, osteoporosis. In spite of, optimistic publications based on small series or isolated clinical cases, these patients present frequent changes of the sexuality and the fertility because of TRAT and gonadotropin dysfunction led by the excessive chronic secretion of progesterone and 17-OHP. A Finnish study reported scores of quality of life better than those of the general population, at 31 men [53] , but there is no study on the sexuality of the patients with severe forms of 21-OHD.
Female fertility
In female with classic CAH the degree of fertility depends on the phenotype of the CAH. The prenatal exposure of androgens virilizes the female fetus in varying degrees depending on the level of 21-hydroxyalse activity, which correlates well to the mutation spectrum. Actually, most fertility problems are seen in the classic salt-wasting type [54] . One of the reasons of the low fertility rate is genital surgery. Indication for surgery should be restrictive given the risk for diminished sensitivity of the clitoris and diminished the risk of pain during intercourse because of the vaginal stenosis [55] . In our cohort, clitoroplasty and vaginoplastie were performed in all but one patients. The first operation was usually performed form 6 months to 8 years of age. They were not re-operated in puberty. They had used a dilator periodically with good results in all who ever had sexual relationship (11/19) . CAH women were not less satisfied with the genital function since none had painful intercourse and none regarded their vagina as tight. However, our results must be interpreted with caution because of more than half reported a complete lack of sexual activity.
Other factor that contributes to impaired fertility in females with CAH is ovarian hyperandrogenism. Women with CAH often have a polycystic ovary-like syndrome. This is generally considered secondary to poor control of the CAH and the consequence of elevated leptin and insulin concentration which may enhance androgen and ovarian production [29] . However, Barnes et al. [56] demonstrated that congenital adrenal virilization programs the hypothalamic-pituitary axis for hyper secretion of LH at puberty. This is postulated to frequency cause ovarian hyperandrogenism even when adrenal androgen excess is subsequently controlled by glucocorticoid therapy. The regulatory of menstrual cycles can be considered as an important measure of therapeutic goal from (per) pubertal years on. Pelvic ultrasonography is recommended at the beginning of puberty and each year at adult age. To our opinion, it is necessary to analyze the ovarian morphology at the end of puberty and then every 2 or 5 years or more often in case of irregularity of the menstrual cycles, poor adequacy to treatment or desire of motherhood.
A few studies have shown a low fertility rate in women CAH [37, 57, 58] . However, the true pregnancy rate is estimate to 91% versus 95% in the general population and similar in the both classic CAH form [57] . Actually a minority of women with CAH wish to become mothers because of vaginal abnormalities, homosexual orientation and psychological factors [58] . Concerning our cohort, we are not in accordance with previously studies. Actually polycystic ovarian were reported in three of them while 17-OHP indicate adequate glucocorticoid treatment. Four had child and all but one have needed in procreation medical assistance.
To conclude, we were not able to compare our results with healthy control women, but the sexual function remained abnormal but was better, as expected. We argue that surgical, medical and psychological treatment can improve quality of life in women with CAH, such as sexual debut, fertility, and sexual relationships.
Management of the adult with congenital adrenal hyperplasia
Mineralocorticoid replacement
Mineralocorticoid replacement with 9-alpha-fludrocortisone acetate, 0.05-0.2 mg/day, is usually continued, with the goal of suppressed renin as low as possible, which blunts the hypovolemic drive to ACTH production. It is recommended to have a normal sodium dietary, since adults are prone to develop hypertension. To titrate mineralocorticoid replacement, the serum potassium concentration and blood pressure in the sitting and standing positions are monitored. The goal is to have normokalemia and lack of orthostasis [14] .
Glucocorticoid replacement
Glucocorticoid replacement therapy remains of central importance in the adult with 21-OHD. Patients are treated to avoid symptoms of adrenocortical deficiency in both sexes; hyperandrogenism, voice changes, and infertility in women, and testicular rest in men. However, supraphysiologic doses, might place patients with 21-OHD at high risk for long-term complications; cardiovascular risk, reduce bone mineral density and adrenal tumors have been described [59] . There are no randomized controlled studies on long-term follow-up of different modes of treatment of adults with classic CAH, and practice varies. Among European pediatric endocrinologists, 36% said they used hydrocortisone (mean dose 13.75 mg/m 2 per day), 14% used prednisolone (4.75 mg/day) and 33% used dexamethasone (0.5 mg/day). Optimal level for 17-OHP and Delta4-androstenedione has not been defined. 17-OHP may be elevated at night, even when morning levels are acceptable. Testosterone levels in men normally reflect gonadal rather than adrenal function and therefore are not useful for monitoring therapy [18] . In our study, all but two had 17-OHP well suppressed in morning. They may receive a supraphysiologic doses but for now any long-term complications were reported. In contrast, one with elevated 17-OHP in morning presented hyperandrogenism manifestations and we detected TRAT on the other patients.
Follow-up protocol
To facilitate monitoring of our patients, we try to propose clinical and paraclinical guidelines in current practice (Appendix A and Appendix B).
Conclusion
The management of the adult with 21-OHD is a humbling and perilous process, given the lack of long-term data and comparative studies. More and more centers around the world manifest interest to this subject. National and international guidelines were proposed. We have to try through this work to analyze which it was made and what should be made in order to improve our current practice. The challenge that remains is to manage better treatments, to suppress the long-term health consequences of this disease and to optimize the quality of life for our patients with CAH.
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